Symbols / RLYB $9.50 +0.96%
RLYB Chart
About
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 50.25M |
| Enterprise Value | -9.43M | Income | -14.17M | Sales | 674.00K |
| Book/sh | 12.03 | Cash/sh | 11.23 | Dividend Yield | — |
| Payout | 0.00% | Employees | 15 | IPO | — |
| P/E | — | Forward P/E | -1.76 | PEG | — |
| P/S | 74.56 | P/B | 0.79 | P/C | — |
| EV/EBITDA | 0.28 | EV/Sales | -13.99 | Quick Ratio | 13.13 |
| Current Ratio | 14.74 | Debt/Eq | 0.31 | LT Debt/Eq | — |
| EPS (ttm) | -2.56 | EPS next Y | -5.40 | EPS Growth | — |
| Revenue Growth | -29.10% | Earnings | 2026-03-16 17:00 | ROA | -28.35% |
| ROE | -21.17% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -32.67% | Profit Margin | 0.00% | Shs Outstand | 5.29M |
| Shs Float | 2.70M | Short Float | 0.88% | Short Ratio | 0.80 |
| Short Interest | — | 52W High | 11.49 | 52W Low | 1.76 |
| Beta | -1.13 | Avg Volume | 123.17K | Volume | 169.35K |
| Target Price | — | Recom | Hold | Prev Close | $9.41 |
| Price | $9.50 | Change | 0.96% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$9.65
Latest analyst target
3. DCF / Fair value
$-74.57
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.65
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-04-15 | down | Jones Trading | Buy → Hold | — |
| 2025-04-09 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-03-17 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-02-12 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-01-13 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-12-03 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-22 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-08 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-10-30 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-10-01 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-09-03 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-08-26 | main | Evercore ISI Group | Outperform → Outperform | $15 |
| 2024-08-12 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-05-15 | down | JP Morgan | Overweight → Neutral | — |
| 2024-05-10 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-04-19 | reit | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2024-04-18 | reit | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2024-04-11 | main | Wedbush | Outperform → Outperform | $11 |
| 2024-03-13 | reit | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2024-03-13 | main | HC Wainwright & Co. | Buy → Buy | $9 |
- RLYB Surges on Revenue and Merger Hype Why the Stock Still Dropped - Bitget ue, 17 Mar 2026 04
- Halper Sadeh LLC is Investigating Whether TALK, JTAI, RLYB are Obtaining Fair Deals for their Shareholders - GlobeNewswire ue, 17 Mar 2026 16
- $RLYB stock is up 31% today. Here's what we see in our data. - Quiver Quantitative Mon, 02 Mar 2026 08
- Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB - Business Wire Wed, 04 Mar 2026 08
- RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders - The AI Journal Mon, 02 Mar 2026 15
- Rallybio Corporation (NASDAQ:RLYB) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat Mon, 02 Mar 2026 08
- Rallybio to Merge with Candid Therapeutics in All-Stock Deal - TipRanks Mon, 02 Mar 2026 08
- Market Movers | Winners: ADIL, ASST, RLYB | Losers: OBAI, GEOS, PFSA - Trefis hu, 05 Feb 2026 08
- Rallybio to Merge With Candid Therapeutics; Candid Holders to Own ~57.6% of Combined Company - TradingView Mon, 02 Mar 2026 14
- Market Movers | Winners: ASST, ADIL, RLYB | Losers: EAF, ERNA, ANEB - Trefis Fri, 06 Feb 2026 08
- Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism - Bitget Mon, 02 Mar 2026 08
- Rallybio to implement 1-for-8 reverse stock split effective February 6 - Investing.com hu, 29 Jan 2026 08
- After-Hours Biotech Watch: IFRX, ABCL, RLYB Among Notable Risers - Nasdaq Sun, 09 Nov 2025 08
- Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 - Benzinga ue, 17 Feb 2026 08
- Rallybio Announces Reverse Stock Split of Common Stock - PharmiWeb.com Wed, 04 Feb 2026 00
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -60.37M | -78.78M | -67.72M | -45.39M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -57.77M | -74.56M | -66.65M | -47.01M |
| ReconciledDepreciation | 131.00K | 150.00K | 167.00K | 109.00K |
| EBITDA | -60.37M | -78.78M | -67.72M | -45.39M |
| EBIT | -60.50M | -78.93M | -67.88M | -45.50M |
| NetInterestIncome | 4.22M | 6.15M | 1.96M | 44.00K |
| InterestExpense | 0.00 | 10.00K | ||
| InterestIncome | 4.22M | 6.15M | 1.96M | 54.00K |
| NormalizedIncome | -57.77M | -74.56M | -66.65M | -47.01M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -57.77M | -74.56M | -66.65M | -47.01M |
| TotalExpenses | 61.13M | 78.93M | 67.88M | 45.65M |
| TotalOperatingIncomeAsReported | -60.50M | -78.93M | -67.88M | -45.65M |
| DilutedAverageShares | 5.44M | 5.06M | 3.98M | 3.19M |
| BasicAverageShares | 5.44M | 5.06M | 3.98M | 3.19M |
| DilutedEPS | -10.64 | -14.72 | -16.72 | -14.72 |
| BasicEPS | -10.64 | -14.72 | -16.72 | -14.72 |
| DilutedNIAvailtoComStockholders | -57.77M | -74.56M | -66.65M | -47.01M |
| NetIncomeCommonStockholders | -57.77M | -74.56M | -66.65M | -47.01M |
| NetIncome | -57.77M | -74.56M | -66.65M | -47.01M |
| NetIncomeIncludingNoncontrollingInterests | -57.77M | -74.56M | -66.65M | -47.01M |
| NetIncomeContinuousOperations | -57.77M | -74.56M | -66.65M | -47.01M |
| EarningsFromEquityInterestNetOfTax | -1.07M | -1.50M | ||
| TaxProvision | 0.00 | |||
| PretaxIncome | -57.77M | -74.56M | -66.65M | -45.51M |
| OtherIncomeExpense | -1.50M | -1.78M | -733.00K | 96.00K |
| OtherNonOperatingIncomeExpenses | 744.00K | 262.00K | 342.00K | 96.00K |
| EarningsFromEquityInterest | -2.24M | -2.04M | -1.07M | |
| NetNonOperatingInterestIncomeExpense | 4.22M | 6.15M | 1.96M | 44.00K |
| InterestExpenseNonOperating | 0.00 | 10.00K | ||
| InterestIncomeNonOperating | 4.22M | 6.15M | 1.96M | 54.00K |
| OperatingIncome | -60.50M | -78.93M | -67.88M | -45.65M |
| OperatingExpense | 61.13M | 78.93M | 67.88M | 45.65M |
| ResearchAndDevelopment | 41.51M | 53.54M | 40.69M | 26.91M |
| SellingGeneralAndAdministration | 19.62M | 25.39M | 27.20M | 18.74M |
| GeneralAndAdministrativeExpense | 19.62M | 25.39M | 27.20M | 18.74M |
| OtherGandA | 19.62M | 25.39M | 27.20M | 18.74M |
| TotalRevenue | 636.00K | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 636.00K | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 5.19M | 4.73M | 4.73M | 4.02M |
| ShareIssued | 5.19M | 4.73M | 4.73M | 4.02M |
| TotalDebt | 154.00K | 392.00K | 555.00K | 0.00 |
| TangibleBookValue | 61.65M | 106.18M | 169.32M | 175.60M |
| InvestedCapital | 61.65M | 106.18M | 169.32M | 175.60M |
| WorkingCapital | 61.60M | 105.53M | 168.75M | 174.32M |
| NetTangibleAssets | 61.65M | 106.18M | 169.32M | 175.60M |
| CapitalLeaseObligations | 154.00K | 392.00K | 555.00K | 0.00 |
| CommonStockEquity | 61.65M | 106.18M | 169.32M | 175.60M |
| TotalCapitalization | 61.65M | 106.18M | 169.32M | 175.60M |
| TotalEquityGrossMinorityInterest | 61.65M | 106.18M | 169.32M | 175.60M |
| StockholdersEquity | 61.65M | 106.18M | 169.32M | 175.60M |
| GainsLossesNotAffectingRetainedEarnings | 68.00K | 15.00K | -214.00K | 0.00 |
| OtherEquityAdjustments | 68.00K | 15.00K | -214.00K | |
| RetainedEarnings | -293.02M | -235.25M | -160.68M | -94.03M |
| AdditionalPaidInCapital | 354.60M | 341.41M | 330.21M | 269.63M |
| CapitalStock | 4.00K | 4.00K | 4.00K | 3.00K |
| CommonStock | 4.00K | 4.00K | 4.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 6.45M | 9.44M | 11.12M | 6.58M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 212.00K | 173.00K | 374.00K | 32.00K |
| NonCurrentAccruedExpenses | 0.00 | 32.00K | ||
| NonCurrentDeferredLiabilities | 212.00K | 0.00 | ||
| NonCurrentDeferredRevenue | 212.00K | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 173.00K | 374.00K | 0.00 |
| LongTermCapitalLeaseObligation | 0.00 | 173.00K | 374.00K | 0.00 |
| CurrentLiabilities | 6.24M | 9.26M | 10.74M | 6.55M |
| CurrentDeferredLiabilities | 848.00K | 0.00 | ||
| CurrentDeferredRevenue | 848.00K | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 154.00K | 219.00K | 181.00K | |
| CurrentCapitalLeaseObligation | 154.00K | 219.00K | 181.00K | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.10M | 3.17M | 4.70M | 2.96M |
| PayablesAndAccruedExpenses | 2.15M | 5.88M | 5.86M | 3.60M |
| CurrentAccruedExpenses | 1.87M | 4.90M | 4.75M | 2.99M |
| Payables | 278.00K | 976.00K | 1.11M | 603.00K |
| AccountsPayable | 278.00K | 976.00K | 1.11M | 603.00K |
| TotalAssets | 68.11M | 115.62M | 180.44M | 182.19M |
| TotalNonCurrentAssets | 267.00K | 831.00K | 939.00K | 1.32M |
| InvestmentsAndAdvances | 0.00 | 239.00K | 30.00K | 805.00K |
| LongTermEquityInvestment | 0.00 | 239.00K | 30.00K | 805.00K |
| InvestmentsinJointVenturesatCost | 0.00 | 239.00K | 30.00K | 805.00K |
| NetPPE | 267.00K | 592.00K | 909.00K | 511.00K |
| AccumulatedDepreciation | -654.00K | -523.00K | -373.00K | -206.00K |
| GrossPPE | 921.00K | 1.11M | 1.28M | 717.00K |
| Leases | 338.00K | 338.00K | 338.00K | 315.00K |
| ConstructionInProgress | 0.00 | 8.00K | ||
| OtherProperties | 524.00K | |||
| MachineryFurnitureEquipment | 431.00K | 431.00K | 420.00K | 394.00K |
| BuildingsAndImprovements | 152.00K | 346.00K | 524.00K | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 67.84M | 114.79M | 179.50M | 180.87M |
| OtherCurrentAssets | 995.00K | 2.05M | 1.05M | 395.00K |
| PrepaidAssets | 1.33M | 2.81M | 9.45M | 5.14M |
| CashCashEquivalentsAndShortTermInvestments | 65.51M | 109.93M | 168.99M | 175.33M |
| OtherShortTermInvestments | 51.61M | 85.44M | 112.04M | 0.00 |
| CashAndCashEquivalents | 13.90M | 24.49M | 56.96M | 175.33M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -49.28M | -60.28M | -57.34M | -45.87M |
| IssuanceOfCapitalStock | 5.41M | 0.00 | 51.53M | 86.20M |
| CapitalExpenditure | -12.00K | -54.00K | -333.00K | |
| EndCashPosition | 13.90M | 24.49M | 56.96M | 175.33M |
| BeginningCashPosition | 24.49M | 56.96M | 175.33M | 140.23M |
| ChangesInCash | -10.59M | -32.46M | -118.38M | 35.10M |
| FinancingCashFlow | 5.20M | 143.00K | 51.08M | 82.97M |
| CashFlowFromContinuingFinancingActivities | 5.20M | 143.00K | 51.08M | 82.97M |
| NetOtherFinancingCharges | -268.00K | -139.00K | -693.00K | -3.23M |
| ProceedsFromStockOptionExercised | 62.00K | 282.00K | 238.00K | 0.00 |
| NetCommonStockIssuance | 5.41M | 0.00 | 51.53M | 86.20M |
| CommonStockIssuance | 5.41M | 0.00 | 51.53M | 86.20M |
| InvestingCashFlow | 33.49M | 27.66M | -112.17M | -2.33M |
| CashFlowFromContinuingInvestingActivities | 33.49M | 27.66M | -112.17M | -2.33M |
| NetInvestmentPurchaseAndSale | 35.49M | 29.92M | -111.82M | 0.00 |
| SaleOfInvestment | 84.42M | 138.33M | 89.50M | 0.00 |
| PurchaseOfInvestment | -48.93M | -108.41M | -201.32M | 0.00 |
| NetBusinessPurchaseAndSale | -2.00M | -2.25M | -300.00K | -2.00M |
| PurchaseOfBusiness | -2.00M | -2.25M | -300.00K | -2.00M |
| NetPPEPurchaseAndSale | 0.00 | -12.00K | -54.00K | -333.00K |
| PurchaseOfPPE | 0.00 | -12.00K | -54.00K | -333.00K |
| OperatingCashFlow | -49.28M | -60.27M | -57.28M | -45.53M |
| CashFlowFromContinuingOperatingActivities | -49.28M | -60.27M | -57.28M | -45.53M |
| ChangeInWorkingCapital | -258.00K | 4.28M | -936.00K | -3.78M |
| ChangeInOtherWorkingCapital | 1.06M | |||
| ChangeInPayablesAndAccruedExpense | -4.04M | -1.54M | 3.71M | 728.00K |
| ChangeInAccruedExpense | -3.34M | -1.44M | 3.22M | 1.70M |
| ChangeInPayable | -698.00K | -99.00K | 487.00K | -976.00K |
| ChangeInAccountPayable | -698.00K | -99.00K | 487.00K | -976.00K |
| ChangeInPrepaidAssets | 2.72M | 5.82M | -4.64M | -4.51M |
| OtherNonCashItems | -1.61M | -3.09M | -435.00K | |
| StockBasedCompensation | 7.99M | 10.92M | 9.50M | 3.65M |
| DepreciationAmortizationDepletion | 131.00K | 150.00K | 167.00K | 109.00K |
| DepreciationAndAmortization | 131.00K | 150.00K | 167.00K | 109.00K |
| OperatingGainsLosses | 2.24M | 2.04M | 1.07M | 1.50M |
| EarningsLossesFromEquityInvestments | 2.24M | 2.04M | 1.07M | 1.50M |
| NetIncomeFromContinuingOperations | -57.77M | -74.56M | -66.65M | -47.01M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RLYB
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|